Isabela Costola Windlin, Bruno Braga Sisnando da Costa, João Paulo Mota Telles, Leonardo B Oliveira, Edwin Koterba, Vitor Nagai Yamaki, Nicollas Nunes Rabelo, Davi Jorge Fontoura Solla, Manoel Jacobsen Teixeira, Eberval Gadelha Figueiredo
{"title":"格列本脲对动脉瘤性蛛网膜下腔出血患者认知能力、生活质量和情绪方面的影响：随机对照试验。","authors":"Isabela Costola Windlin, Bruno Braga Sisnando da Costa, João Paulo Mota Telles, Leonardo B Oliveira, Edwin Koterba, Vitor Nagai Yamaki, Nicollas Nunes Rabelo, Davi Jorge Fontoura Solla, Manoel Jacobsen Teixeira, Eberval Gadelha Figueiredo","doi":"10.1016/j.wneu.2024.09.048","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Aneurysmal subarachnoid hemorrhage (aSAH) is associated with a high incidence of long-term cognitive impairment, decreased quality of life (QoL), and psychiatric disorders. The effects of glibenclamide on such outcomes in the setting of aSAH is unknown.</p><p><strong>Objective: </strong>To assess the impact of glibenclamide in patients with aSAH on cognitive performance, QoL, and emotional aspects.</p><p><strong>Methods: </strong>Patients identified with aSAH were randomly allocated to receive 5mg of glibenclamide for 21 days or placebo, starting within 96 hours of the ictus. After six months, patients were evaluated with MoCA test (cognitive performance), SF-36 (QoL), and HADS and SPTSS (emotional aspects).</p><p><strong>Results: </strong>The mean MoCA score was 22.5 ± 6.2. No statistically significant difference was found between groups, with a mean score of 21.7 ± 6.4 in the Glibeclamide group and 23.4 ± 6.2 in the placebo group (p=0.392). A score <23 was observed in 16 patients (35.6%) and its frequency was similar between groups (p=0.900). The most frequently impaired domains were Attention (N=21/45; 46.7%) and Visuospatial (18/45; 40.0%). Impairment of each domain was similar between groups (p>0.05). In each domain, the mean score was similar between groups (p>0.05). The HADS scores did not differ between groups (p>0.05). The mean SPTSS score as well as the mean scores of its domains were similar between groups (p>0.05).</p><p><strong>Conclusions: </strong>Glibenclamide did not improve cognitive performance, QoL, and emotional aspects after six months of follow-up of aSAH survivors.</p>","PeriodicalId":23906,"journal":{"name":"World neurosurgery","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"THE EFFECTS OF GLIBENCLAMIDE ON COGNITIVE PERFORMANCE, QUALITY OF LIFE, AND EMOTIONAL ASPECTS AMONG PATIENTS WITH ANEURYSMAL SUBARACHNOID HEMORRHAGE: A RANDOMIZED CONTROLLED TRIAL.\",\"authors\":\"Isabela Costola Windlin, Bruno Braga Sisnando da Costa, João Paulo Mota Telles, Leonardo B Oliveira, Edwin Koterba, Vitor Nagai Yamaki, Nicollas Nunes Rabelo, Davi Jorge Fontoura Solla, Manoel Jacobsen Teixeira, Eberval Gadelha Figueiredo\",\"doi\":\"10.1016/j.wneu.2024.09.048\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Aneurysmal subarachnoid hemorrhage (aSAH) is associated with a high incidence of long-term cognitive impairment, decreased quality of life (QoL), and psychiatric disorders. The effects of glibenclamide on such outcomes in the setting of aSAH is unknown.</p><p><strong>Objective: </strong>To assess the impact of glibenclamide in patients with aSAH on cognitive performance, QoL, and emotional aspects.</p><p><strong>Methods: </strong>Patients identified with aSAH were randomly allocated to receive 5mg of glibenclamide for 21 days or placebo, starting within 96 hours of the ictus. After six months, patients were evaluated with MoCA test (cognitive performance), SF-36 (QoL), and HADS and SPTSS (emotional aspects).</p><p><strong>Results: </strong>The mean MoCA score was 22.5 ± 6.2. No statistically significant difference was found between groups, with a mean score of 21.7 ± 6.4 in the Glibeclamide group and 23.4 ± 6.2 in the placebo group (p=0.392). A score <23 was observed in 16 patients (35.6%) and its frequency was similar between groups (p=0.900). The most frequently impaired domains were Attention (N=21/45; 46.7%) and Visuospatial (18/45; 40.0%). Impairment of each domain was similar between groups (p>0.05). In each domain, the mean score was similar between groups (p>0.05). The HADS scores did not differ between groups (p>0.05). The mean SPTSS score as well as the mean scores of its domains were similar between groups (p>0.05).</p><p><strong>Conclusions: </strong>Glibenclamide did not improve cognitive performance, QoL, and emotional aspects after six months of follow-up of aSAH survivors.</p>\",\"PeriodicalId\":23906,\"journal\":{\"name\":\"World neurosurgery\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-09-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World neurosurgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.wneu.2024.09.048\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World neurosurgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.wneu.2024.09.048","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
THE EFFECTS OF GLIBENCLAMIDE ON COGNITIVE PERFORMANCE, QUALITY OF LIFE, AND EMOTIONAL ASPECTS AMONG PATIENTS WITH ANEURYSMAL SUBARACHNOID HEMORRHAGE: A RANDOMIZED CONTROLLED TRIAL.
Introduction: Aneurysmal subarachnoid hemorrhage (aSAH) is associated with a high incidence of long-term cognitive impairment, decreased quality of life (QoL), and psychiatric disorders. The effects of glibenclamide on such outcomes in the setting of aSAH is unknown.
Objective: To assess the impact of glibenclamide in patients with aSAH on cognitive performance, QoL, and emotional aspects.
Methods: Patients identified with aSAH were randomly allocated to receive 5mg of glibenclamide for 21 days or placebo, starting within 96 hours of the ictus. After six months, patients were evaluated with MoCA test (cognitive performance), SF-36 (QoL), and HADS and SPTSS (emotional aspects).
Results: The mean MoCA score was 22.5 ± 6.2. No statistically significant difference was found between groups, with a mean score of 21.7 ± 6.4 in the Glibeclamide group and 23.4 ± 6.2 in the placebo group (p=0.392). A score <23 was observed in 16 patients (35.6%) and its frequency was similar between groups (p=0.900). The most frequently impaired domains were Attention (N=21/45; 46.7%) and Visuospatial (18/45; 40.0%). Impairment of each domain was similar between groups (p>0.05). In each domain, the mean score was similar between groups (p>0.05). The HADS scores did not differ between groups (p>0.05). The mean SPTSS score as well as the mean scores of its domains were similar between groups (p>0.05).
Conclusions: Glibenclamide did not improve cognitive performance, QoL, and emotional aspects after six months of follow-up of aSAH survivors.
期刊介绍：
World Neurosurgery has an open access mirror journal World Neurosurgery: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review.
The journal''s mission is to:
-To provide a first-class international forum and a 2-way conduit for dialogue that is relevant to neurosurgeons and providers who care for neurosurgery patients. The categories of the exchanged information include clinical and basic science, as well as global information that provide social, political, educational, economic, cultural or societal insights and knowledge that are of significance and relevance to worldwide neurosurgery patient care.
-To act as a primary intellectual catalyst for the stimulation of creativity, the creation of new knowledge, and the enhancement of quality neurosurgical care worldwide.
-To provide a forum for communication that enriches the lives of all neurosurgeons and their colleagues; and, in so doing, enriches the lives of their patients.
Topics to be addressed in World Neurosurgery include: EDUCATION, ECONOMICS, RESEARCH, POLITICS, HISTORY, CULTURE, CLINICAL SCIENCE, LABORATORY SCIENCE, TECHNOLOGY, OPERATIVE TECHNIQUES, CLINICAL IMAGES, VIDEOS
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
